Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company ...

Josh Lipton takes a closer look at the top stories on Wall Street on today's Market Minute: NewsMax (NMAX) stock skyrockets ...

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Corcept Therapeutics (NASDAQ:CORT – Free Report) had its target price lifted by Piper Sandler from $128.00 to $131.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...

Stock analysts at Zacks Research raised their Q2 2026 EPS estimates for shares of Corcept Therapeutics in a research note issued to investors on Wednesday, April 2nd. Zacks Research analyst K. Das now ...

Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics CORT. And retail traders should ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Corcept Therapeutics Incorporated’s CORT share price has surged by 110.16%, which has investors questioning if this is right ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...